3 results
The purpose of this study is to compare the MR formulations with the IR formulation. It will be investigated to what extent the MR formulations of Ivabradine are tolerated. In addition, it will be investigated how quickly and to what extent the MR…
The primary objective of this study is to determine the ability of reslizumab (110 mg) administered subcutaneously (sc) once every 4 weeks to produce a corticosteroid-sparing effect (as demonstrated by percent reduction in daily OCS use) in patients…
The primary objective of this study is to determine whether reslizumab, at a dosage of 0.3 or 3.0 mg/kg administered once every 4 weeks for a total of 4 doses, is more effective than placebo in improving lung function in patients with eosinophilic…